The Experts below are selected from a list of 9 Experts worldwide ranked by ideXlab platform
E. Arrigoni Martelli - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of in vitro and in vivo antimicrobial activity of a new Topical Antiinfective Agent.
Drugs under experimental and clinical research, 1995Co-Authors: C. M. D'urso, G. Gramiccioli, S. Mirri, P. Foresta, E. Arrigoni MartelliAbstract:ST 1103 (Undecyl [4-N,N,N-trimethylammonium-(R)-3- isovaleroyloxy]-butanoate methanesulfonate) is a novel compound endowed with a broad antimicrobial spectrum. ST 1103 is able to inhibit the in vitro growth of Gram-positive bacteria (mean MIC value of 2.60 micrograms/ml), Gram-negative bacteria (mean MIC value of 27.00 micrograms/ml), yeasts and yeast-like fungi (mean MIC value of 3.76 micrograms/ml), filamentous and dermatophytic fungi (mean MIC value of 18.33 micrograms/ml). Since indirect evidence indicates a poor oral absorbtion, ST 1103 was Topically administered to mice with skin infections caused by mixed inocula. In these conditions, ST 1103 was able to cure mice infected with T. quinckeanum, S. aureus as well as immunodepressed mice infected with T. quinckeanum, S. aureus and C. albicans. Conversely, miconazole (reference compound) appeared inadequate, in our experimental conditions, for a definitive therapy of the skin mycosis superinfected by staphylococcus. By using an in vitro 3D-human skin model, ST 1103 was fairly well tolerated in terms of both cell viability and release of inflammatory mediators. In a dermal tolerance study in mice, ST 1103 at a concentration of 1% did not show any sign of local irritation on both intact and abraded skin after an 8-day Topical treatment. In conclusion, ST 1103 appears to be a promising candidate for treatment of cutaneous infections caused by mixed microbial pathogens.
Khalid Hassan Mohmed Ismail Elbeely - One of the best experts on this subject based on the ideXlab platform.
-
IN-VITRO COMPARISON TO EVALUATE THE EFFECT OF DIFFERENT VEHICLES IN THE EFFECTIVENESS OF TopicalLY APPLIED MUPIROCIN
Journal of Science and Technology, 2009Co-Authors: Khalid Hassan Mohmed Ismail ElbeelyAbstract:The efficacy of a new Topical Antiinfective Agent, mupirocin in different vehicles, was compared with that of oral erythromyc in.The relative activity of Mupirocin in Topically applied formulations using different vehicles (ointment and cream) versus oral erythromycin was evaluated by antimicrobial activity studies. Vehicles can play a great role in enhancin g drug release and imparting superior antimicrobial activity when the drug was e ntirely solubilized. Furthermore, drug release and in vivo response demonstrated the usefulness of in vitro release studies in predicting vehicle effi cacy. The evaluation of ointment and Mupirocin cream vehicles with oral erythromycin were studied in experimental skin infections. A mouse surgical wound model infected with Staphylococcus aureus or Streptococcus pyogenes was used. Topical Mupirocin treatment was applied at 4 and 10 h postinfection oral erythromycin treatment at a c linically relevant dose was administered 4, 8, and 12 h postinfection; treatments were continued three times daily for a further 3 days. Mupirocin c ream was significantly more effective than ( P < 0.01; two of eight studies) Mupirocin ointment in reducin g bacterial numbers. Mupirocin cream was similar in e fficacy to oral erythromycin. .Mupirocin cream had efficacy to agai nst S. aureus but was significantly superior against S. pyogenes (P < 0.01). A hamster impetigo model infected with S. aureus was also used. Topical Mupirocin or oral erythromycin treatment was administered at 24 and 30 h postinfec tion (also 36 h postinfection for oral therapy) and then three times daily for a further 2 days. On day 5, Mupirocin cream was significantly more effective than Mupirocin ointment in the study (P < 0.01). In impetigo infection Mupirocin cream was significa ntly superior (P < 0.01) to oral erythromycin against S. aureus .
H. Siddique - One of the best experts on this subject based on the ideXlab platform.
-
IN-VITRO COMPARISON TO EVALUATE THE EFFECT OF DIFFERENT VEHICLES IN THE EFFECTIVENESS OF TopicalLY APPLIED MUPIROCIN BY
2016Co-Authors: H. S. Ali, I. El-neima, H. SiddiqueAbstract:The efficacy of a new Topical Antiinfective Agent, mupirocin in different vehicles, was compared with that of oral erythromycin.The relative activity of Mupirocin in Topically applied formulations using different vehicles (ointment and cream) versus oral erythromycin was evaluated by antimicrobial activity studies. Vehicles can play a great role in enhancing drug release and imparting superior antimicrobial activity when the drug was entirely solubilized. Furthermore, drug release and in vivo response demonstrated the usefulness of in vitro release studies in predicting vehicle efficacy. The evaluation of ointment and Mupirocin cream vehicles with oral erythromycin were studied in experimental skin infections. A mouse surgical wound model infected with Staphylococcus aureus or Streptococcus pyogenes was used. Topical Mupirocin treatment was applied at 4 and 10 h postinfection oral erythromycin treatment at a clinically relevant dose was administered 4, 8, and 12 h postinfection; treatments were continue
C. M. D'urso - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of in vitro and in vivo antimicrobial activity of a new Topical Antiinfective Agent.
Drugs under experimental and clinical research, 1995Co-Authors: C. M. D'urso, G. Gramiccioli, S. Mirri, P. Foresta, E. Arrigoni MartelliAbstract:ST 1103 (Undecyl [4-N,N,N-trimethylammonium-(R)-3- isovaleroyloxy]-butanoate methanesulfonate) is a novel compound endowed with a broad antimicrobial spectrum. ST 1103 is able to inhibit the in vitro growth of Gram-positive bacteria (mean MIC value of 2.60 micrograms/ml), Gram-negative bacteria (mean MIC value of 27.00 micrograms/ml), yeasts and yeast-like fungi (mean MIC value of 3.76 micrograms/ml), filamentous and dermatophytic fungi (mean MIC value of 18.33 micrograms/ml). Since indirect evidence indicates a poor oral absorbtion, ST 1103 was Topically administered to mice with skin infections caused by mixed inocula. In these conditions, ST 1103 was able to cure mice infected with T. quinckeanum, S. aureus as well as immunodepressed mice infected with T. quinckeanum, S. aureus and C. albicans. Conversely, miconazole (reference compound) appeared inadequate, in our experimental conditions, for a definitive therapy of the skin mycosis superinfected by staphylococcus. By using an in vitro 3D-human skin model, ST 1103 was fairly well tolerated in terms of both cell viability and release of inflammatory mediators. In a dermal tolerance study in mice, ST 1103 at a concentration of 1% did not show any sign of local irritation on both intact and abraded skin after an 8-day Topical treatment. In conclusion, ST 1103 appears to be a promising candidate for treatment of cutaneous infections caused by mixed microbial pathogens.
G. Gramiccioli - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of in vitro and in vivo antimicrobial activity of a new Topical Antiinfective Agent.
Drugs under experimental and clinical research, 1995Co-Authors: C. M. D'urso, G. Gramiccioli, S. Mirri, P. Foresta, E. Arrigoni MartelliAbstract:ST 1103 (Undecyl [4-N,N,N-trimethylammonium-(R)-3- isovaleroyloxy]-butanoate methanesulfonate) is a novel compound endowed with a broad antimicrobial spectrum. ST 1103 is able to inhibit the in vitro growth of Gram-positive bacteria (mean MIC value of 2.60 micrograms/ml), Gram-negative bacteria (mean MIC value of 27.00 micrograms/ml), yeasts and yeast-like fungi (mean MIC value of 3.76 micrograms/ml), filamentous and dermatophytic fungi (mean MIC value of 18.33 micrograms/ml). Since indirect evidence indicates a poor oral absorbtion, ST 1103 was Topically administered to mice with skin infections caused by mixed inocula. In these conditions, ST 1103 was able to cure mice infected with T. quinckeanum, S. aureus as well as immunodepressed mice infected with T. quinckeanum, S. aureus and C. albicans. Conversely, miconazole (reference compound) appeared inadequate, in our experimental conditions, for a definitive therapy of the skin mycosis superinfected by staphylococcus. By using an in vitro 3D-human skin model, ST 1103 was fairly well tolerated in terms of both cell viability and release of inflammatory mediators. In a dermal tolerance study in mice, ST 1103 at a concentration of 1% did not show any sign of local irritation on both intact and abraded skin after an 8-day Topical treatment. In conclusion, ST 1103 appears to be a promising candidate for treatment of cutaneous infections caused by mixed microbial pathogens.